KONEXBiotech & Pharma200580

Medyssey

₩11,410▲ 2.06%2026-10-02 close

Market Cap

₩42.5B

Turnover

₩6,379,430

Volume

569 shares

Shares out.

3.7M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Korea's Spine Implant No.1 on 57% Export Revenue

Medyssey, a subsidiary of Dongwha Pharmaceutical and Korea's top spine implant maker, posted consolidated revenue of KRW 28.3bn and operating profit of KRW 4.0bn in FY2025, sustaining five consecutive years of growth.

1
FY2025 consolidated revenue KRW 28.3bn, operating profit KRW 4.0bn, net income KRW 3.3bn; ~9% five-year revenue CAGR (Financial News, May 2026)
2
FY2025 export revenue of KRW 16.4bn accounts for 57.82% of total; dollar-denominated global sales exceeded USD 10mn for three consecutive years (2022–2024)
3
First Korean med-tech firm to adopt metal 3D printing; largest domestic 3D printing infrastructure—related revenue grew 29% in FY2024
4
Dongwha Pharmaceutical is preparing a KOSDAQ transfer listing (Dailypharm, Jan 2026)—potential catalyst for meaningful liquidity improvement
5
Four overseas subsidiaries (US, Chile, Thailand, and others) and 25-country export network underpin structural demand tailwind from global aging trends

Business structure

Medyssey (MEDYSSEY CO.,LTD.) was established in Gyeonggi-do in 2003 as a spine surgical implant manufacturer; it changed its name in 2007 and listed on KONEX in October 2015.

Its flagship products are screw-and-rod fixation implants used in spinal fusion surgery for orthopedic and neurosurgical applications, with thoracolumbar (thoracic and lumbar spine) implants accounting for more than 80% of total revenue.

The company holds a full spine implant product lineup and secured a key regulatory milestone in 2017 with US FDA clearance for a 3D-printed porous interbody fusion device, establishing international regulatory credibility.

Medyssey was the first Korean medical device firm to adopt metal 3D printing equipment for patient-specific customized implants and now operates the largest 3D printing infrastructure among domestic med-tech peers.

Its international operations are structured around four wholly-owned overseas subsidiaries—in the United States, Chile, Thailand, and one additional market—and a 50%-owned joint venture in Chongqing, China; exports have consistently exceeded 53% of revenue over the past five years, making it an export-led business.

In 2020, Dongwha Pharmaceutical invested approximately KRW 22.1bn to acquire Medyssey, marking the pharma company's first-ever M&A in its 123-year history.

Domestically, Medyssey holds the top position in the Korean spine implant market, but competes globally against multinational giants such as DePuy Synthes, Medtronic, and Stryker, and domestically against peers including LNK BioMed and Osteonic.

The company holds 15 patents and 13 trademarks in spine implant-related technologies, underpinning sustained R&D efforts through its in-house corporate research institute.

Recent trends

Based on reports from May 2026, Medyssey delivered consolidated FY2025 revenue of KRW 28.3bn, operating profit of KRW 4.0bn, and net income of KRW 3.3bn, improving both top-line and profitability compared to the prior year.

Over the past five years, the company has achieved approximately 9% annual revenue CAGR, growing from KRW 20.8bn in FY2021, to KRW 24.6bn in FY2022, KRW 26.5bn in FY2023, KRW 25.5bn in FY2024, and KRW 28.3bn in FY2025.

In FY2024, won-denominated total revenue declined approximately 4% year-on-year, while dollar-denominated global exports reached USD 10.63mn, up 10% YoY—a divergence attributable to KRW/USD fluctuations affecting the translation of foreign-currency revenue.

FY2025 export revenue of KRW 16.4bn accounted for 57.82% of total sales, with the company securing export records in 27 countries over the past three years. Revenue from 3D printing-based products grew 29% from KRW 590mn in FY2023 to KRW 760mn in FY2024, establishing it as a credible secondary growth driver.

Operating profit rebounded sharply (+45%) in FY2024 and continued to improve in FY2025, bringing the operating margin to approximately 14.1%, reflecting successful cost discipline.

Notably, FY2023 saw operating profit plunge over 40% year-on-year despite 7.9% revenue growth, underscoring the near-term earnings volatility that remains a consideration.

In May 2025, Medyssey received the top management award at the Korea KONEX Grand Prix, co-organized by MoneyToday and Korea Exchange, recognizing its stable performance and growth trajectory.

As of the reference date, the share price stands at KRW 11,800, but near-zero daily trading volume—a structural KONEX characteristic—continues to materially constrain liquidity.

Outlook

Medyssey's stated growth strategy centers on country-specific product development and the expansion of overseas regulatory approvals. Global aging and rising spinal disease prevalence provide a structural long-term tailwind for spine implant market demand.

Continued growth from US and Chile subsidiaries, along with expanded Asian market penetration, is expected to sustain export revenue gains, while the 3D printing customized implant segment—growing at 20–30% annually—presents a meaningful medium-term opportunity to improve the revenue mix and margins.

Reports from January 2026 (Dailypharm) indicate that Dongwha Pharmaceutical is preparing a KOSDAQ transfer listing for Medyssey, which, if completed, could materially improve liquidity and institutional investor access, representing the single most significant medium-term catalyst.

Near-term uncertainties include potential KRW appreciation, which could compress won-denominated export revenue; shifts in US medical device tariff policy; and tightening import regulations in key export markets.

The key execution challenge is sustaining profitable growth by balancing accelerated international regulatory submissions with disciplined cost management in SG&A and manufacturing.

Bull factors

Export-Led Growth Firmly on Track

Export revenue reached 57.82% of total sales in FY2025, backed by a global distribution network spanning 25 countries anchored by wholly-owned subsidiaries in the US, Chile, and Thailand.

Dollar-denominated global sales maintained the USD 10mn+ threshold for three consecutive years—USD 10.74mn in 2022, USD 10.10mn in 2023, and USD 10.63mn in 2024—validating a durable export base.

Further Asian market penetration and expanding regulatory approvals in emerging markets could accelerate the export growth rate, while the five-year revenue CAGR of approximately 9% signals the continued validity of structural growth drivers.

3D Printing Leadership Drives High-Value Product Shift

Medyssey was the first Korean medical device company to introduce metal 3D printing equipment and now operates the largest 3D printing infrastructure among domestic peers, positioning it as a clear technology leader.

Revenue from 3D printing-based products grew 29% in FY2024 versus FY2023, and customized patient-specific implants command materially higher per-unit value than standard implants, offering meaningful margin improvement potential.

The company's 2017 US FDA clearance for a 3D-printed porous interbody device provides tangible evidence of global regulatory credibility, while the broader global trend toward customized, high-value medical devices represents a structural tailwind that disproportionately benefits Medyssey.

Dongwha Group Backing and KOSDAQ Upgrade Optionality

Since joining Dongwha Pharmaceutical's group in 2020, Medyssey has achieved simultaneous improvement in revenue growth and profitability, underpinned by the parent company's financial strength and brand credibility.

Reports of a KOSDAQ transfer listing preparation signal that the parent is actively pursuing Medyssey's enterprise value enhancement; if completed, this could meaningfully improve institutional investor access and unlock a liquidity premium.

The approximately 9% annual revenue CAGR and the profitability recovery observed in FY2024 and FY2025 reflect successful operational synergies and reinforced global sales strategy under Dongwha's stewardship.

Bear factors

Structural KONEX Illiquidity Constrains Investability

As of the reference date (June 7, 2026), daily trading volume was effectively KRW 0—a structural feature of the KONEX market that severely constrains practical investability.

In a near-zero liquidity environment, even modest sell orders can cause outsized price movements, and institutional investor access is inherently restricted.

This liquidity risk is unlikely to be resolved until a KOSDAQ transfer listing is completed, presenting a practical barrier for both retail and institutional investors seeking entry or exit.

Near-Term Earnings Volatility and Currency Sensitivity

FY2023 saw operating profit plunge more than 40% year-on-year despite 7.9% revenue growth, confirming that near-term earnings volatility can be significant. This implies that in periods where cost inflation or SG&A growth outpaces revenue, profitability can be sharply impaired.

With exports exceeding 57% of revenue, a strengthening Korean won creates meaningful pressure on won-denominated export sales—illustrated by FY2024, when dollar-denominated global exports grew 10% while total won-denominated revenue declined 4%.

Scale Gap Versus Global Spine Implant Giants

The global spine implant market is dominated by a small number of large multinationals—DePuy Synthes (J&J), Medtronic, and Stryker—against whom Medyssey's scale gap is enormous.

At KRW 28.3bn in FY2025 revenue, Medyssey operates at a fraction of these competitors' sales, constraining its capacity to invest in R&D, marketing, and regulatory compliance at a comparable pace.

Domestically, competition is also intensifying as peers such as LNK BioMed, Osteonic, and Sijimedtech aggressively pursue technology upgrades, while the cost and time required for international regulatory submissions represent additional constraints on growth velocity.

Risk factors

Macro & Currency Risk

With exports exceeding 57% of total revenue, a meaningful KRW appreciation would significantly compress won-denominated revenue and earnings through translation effects. A global economic slowdown or reduction in healthcare spending in key export markets could reduce surgical volumes and implant demand.

Changes in US medical device tariff policy or tightening import regulations in key export countries represent additional macro variables that could adversely affect Medyssey's trading environment.

Sector & Competition Risk

Accelerating M&A activity and technological innovation by global spine implant majors pose a structural threat to mid-sized players' market share.

Domestic peers are also intensifying investments in advanced technologies such as 3D printing and navigation systems, meaning Medyssey's technology leadership position faces continuous challenge.

A product recall or quality incident could rapidly and severely damage brand credibility and revenue, making rigorous quality management a critical ongoing risk-control priority.

Regulatory Risk

Obtaining regulatory approvals in overseas markets is resource-intensive and time-consuming, and key markets such as the US FDA and European MDR are subject to continuously tightening requirements.

Delays or rejections in regulatory submissions could disrupt exports to specific countries, directly impacting revenue given the company's high export dependency.

Domestically, changes in national health insurance reimbursement policy or medical device price reduction pressure are regulatory risks that could negatively affect domestic profitability.

Overall view

Medyssey holds a clear competitive position as Korea's top spine implant maker, with a 57%-plus export revenue base validated across 25 markets, differentiated metal 3D printing capability, and the backing of a stable parent in Dongwha Pharmaceutical.

The company has demonstrated simultaneous improvement in top-line growth and profitability, with approximately 9% annual revenue CAGR over five years and an operating margin of approximately 14% in FY2025.

A potential KOSDAQ transfer listing is the most significant medium-term catalyst, as it could dramatically improve liquidity and institutional accessibility.

However, as long as Medyssey remains on KONEX, near-zero daily trading volume constitutes a meaningful practical barrier for all investor types, limiting the actionability of the investment thesis in the near term.

Near-term earnings volatility—exemplified by the FY2023 operating profit collapse—and currency translation sensitivity on export revenues warrant continuous monitoring.

On balance, while underlying business fundamentals are constructive, liquidity constraints and earnings variability argue for a Neutral stance; key watchpoints are any DART filings related to the KOSDAQ transfer listing and progress on international regulatory approvals.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 11 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.